Immix Biopharma, Inc. (IMMX) - Latest Market Data

Track the most recent price, market cap, volume, and performance data for Immix Biopharma, Inc. (IMMX).

Download StockRank on Google Play Download StockRank on the App Store

Equity Overview

Price & Market Data

Price: $2.45

Daily Change: -$0.145 / 5.92%

Daily Range: $2.35 - $2.74

Market Cap: $66,626,748

Daily Volume: 366,895

Performance Metrics

1 Week: -12.13%

1 Month: -13.09%

3 Months: 12.74%

6 Months: 18.32%

1 Year: 9.63%

YTD: 8.64%

Company Details

Employees: 21

Sector: Health technology

Industry: Pharmaceuticals: major

Country:

Details

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Selected stocks

Crown Castle Inc. (CCI)

SBA Communications Corporation (SBAC)

Corning Incorporated (GLW)